Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension

Despite the availability of a wide range of antihypertensive treatments, due to the multifactorial nature of hypertension many patients still fail to achieve blood pressure (BP) control. The recent ESC/ESH, WHO and ISH guidelines for the treatment of hypertension now recommend the preferential use of a single-pill combination (SPC) and patient management that takes into account the severity of BP and the presence of other cardiovascular risk factors. Four large observational studies have recently assessed the efficacy of a perindopril 10 mg/indapamide 2.5 mg (Per 10/Ind 2.5) SPC in patients with hypertension uncontrolled on their previous treatment. Patients had a range of associated risk factors and comorbidities, making the cohort representative of patients followed in daily medical practice. The raw data from these studies were pooled to provide results in cohorts of sufficient sample size to assess the SPC effects, and this is the first large pooled analysis performed with the high dose Per/Ind SPC (N = 16,763).

What was learned from the study?

Switching to a Per/Ind 10/2.5 SPC led to rapid and statistically significant reductions in BP with 70% of previously uncontrolled patients achieving normalized values at 3 months. The beneficial effects were demonstrated in all subgroups, including those with comorbidities and those requiring triple antihypertensive therapy. Treatment with the Per/Ind SPC was well tolerated and metabolically neutral.